Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Research & Development (2016 - 2025)

Amphastar Pharmaceuticals has reported Research & Development over the past 13 years, most recently at $23.3 million for Q4 2025.

  • Quarterly results put Research & Development at $23.3 million for Q4 2025, up 28.51% from a year ago — trailing twelve months through Dec 2025 was $85.8 million (up 16.14% YoY), and the annual figure for FY2025 was $85.8 million, up 16.14%.
  • Research & Development for Q4 2025 was $23.3 million at Amphastar Pharmaceuticals, up from $22.4 million in the prior quarter.
  • Over the last five years, Research & Development for AMPH hit a ceiling of $23.3 million in Q4 2025 and a floor of $10.8 million in Q3 2021.
  • Median Research & Development over the past 5 years was $18.1 million (2021), compared with a mean of $18.5 million.
  • Biggest five-year swings in Research & Development: tumbled 39.02% in 2021 and later surged 72.08% in 2022.
  • Amphastar Pharmaceuticals' Research & Development stood at $17.3 million in 2021, then dropped by 0.29% to $17.2 million in 2022, then increased by 18.47% to $20.4 million in 2023, then decreased by 11.15% to $18.1 million in 2024, then increased by 28.51% to $23.3 million in 2025.
  • The last three reported values for Research & Development were $23.3 million (Q4 2025), $22.4 million (Q3 2025), and $20.1 million (Q2 2025) per Business Quant data.